NeuRecover-SA™ in the Treatment of Cocaine Withdrawal and Craving

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Clinical Drug Investigation

• Publication date

  1996-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2165/00044011-199612010-00001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials.

  1995cited by this paper
• Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence.

  1995cited by this paper
• Imipramine treatment of cocaine abuse: possible boundaries of efficacy.

  1995cited by this paper
• Carbamazepine treatment of cocaine dependence: a placebo-controlled trial.

  1995cited by this paper
• Carbamazepine treatment for cocaine dependence.

  1995cited by this paper
• The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function.

  1995cited by this paper
• An examination of the cocaine relapse process.

  1995cited by this paper
• The Chemical Use, Abuse, and Dependence Scale (CUAD). Rationale, reliability, and validity.

  1992cited by this paper
• The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale.

  1991cited by this paper
• Drug abuse in schizophrenic patients: clinical correlates and reasons for use.

  1991cited by this paper
• Pharmacologic Treatment of Cocaine Abuse

  1991cited by this paper
• Cocaine Abuse and Its Treatment

  1990cited by this paper
• Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient tropamine

  1988cited by this paper
• Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine.

  1988cited by this paper

• Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs

  2024cites this paper
• Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis

  2023cites this paper
• Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

  2022cites this paper
• Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis

  2021cites this paper
• Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch.

  2020cites this paper
• Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD

  2018cites this paper
• Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS)

  2017cites this paper
• Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term

  2016cites this paper
• Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.

  2016cites this paper
• Hypothesizing “Reward” Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: A Nutrient and Electrotherapeutic Based Solution

  2014cites this paper
• Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

  2012cites this paper
• A study of cocaine use in Northern Ireland 2009.

  2011cites this paper
• Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms

  2011cites this paper
• Synaptamine (SG8839),TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS)

  2007cites this paper
• Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome

  2007cites this paper
• Pharmacological treatment of cocaine dependence: a systematic review.

  2002influential citation
• The rational use of drugs as therapeutic agents for the treatment of the alcoholisms.

  1998cites this paper
• Enhancement of Attention Processing by Kantroll™ in Healthy Humans: A Pilot Study

  1997cites this paper
• Clinical evidence for effectiveness of phencal in maintaining weight loss in an open-label, controlled, 2-year study

  1997cites this paper